Company intelligence / Profile preview

IO Investigación

Copenhagen, Denmarkioinvestigacion.com ↗

Ownership: Private
Development stage: Other

Overview

IO Biotech's lead program, a combination vaccine targeting IDO1 and PD-L1 antigens (IO102-IO103), is in Phase III trials for advanced melanoma. Interim analyses have shown promising response rates and safety profiles when combined with pembrolizumab. The primary endpoint of progression-free survival is expected to be reached in the first half of 2025. Earlier studies showed a complete response rate of up to ~45% and overall response rates near ~79% when combined with checkpoint inhibitors.[6][10]

Therapeutic areas: Oncology
Modalities: Vaccine
Industry: Biotech

Partnerships

Merck/MSD

Beyond the preview

Go deeper on IO Investigación.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IO Investigación.

Explore the full profile